Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00257205 · ClinicalTrials.gov registry record · Phase 3
CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 655
- Enrollment target
NCT00257205 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 655 participants.
The verdict
NCT00257205, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 655 participants
- Enrollment target
Study Summary
This is a Phase 3, multi-national, open-label, 2-arm randomized study in patients with surgically incurable metastatic melanoma who have received no prior chemotherapy, or biochemotherapy for the treatment of metastatic disease. The primary objective of this trial is to compare overall survival for patients with advanced melanoma who are randomized to receive CP-675,206 with that of patients who are randomized to receive either dacarbazine or temozolomide (investigator choice)
Interventions
- DRUG temozolomide
- DRUG dacarbazine
- DRUG CP-675,206
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 655 participants |
| Start Date | 2006-03 |
| Est. Completion | 2010-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00257205
The ClinicalTrials.gov registry entry for NCT00257205 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 655 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which temozolomide is the first listed.
NCT00257205 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00257205 about?
NCT00257205 is a clinical study titled "CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy". This is a Phase 3, multi-national, open-label, 2-arm randomized study in patients with surgically incurable metastatic melanoma who have received no prior chemotherapy, or biochemotherapy for the treatment of metastatic disease. The primary objective of this trial is to compare overall survival for ...
What is the current status of trial NCT00257205?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 655 participants. The study started on 2006-03. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00257205?
The interventions under investigation include: temozolomide (DRUG), dacarbazine (DRUG), CP-675,206 (DRUG).
Who is sponsoring clinical trial NCT00257205?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.